Nkarta Inc (NKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $85.23M
Last updated: Nov 17, 2026 at 11:05 AM ET
Nkarta Inc (NKTX) Competitors
The companies most similar to Nkarta are Mink Therapeutics (INKT), NRX Pharmaceuticals (NRXP) and OnKure Therapeutics (OKUR). By market cap, Nkarta ranks 6th of the 13 companies on this page; Protara Therapeutics (TARA) is the largest at $155.77M.
Peer Comparison
NKTX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Nkarta (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Mink Therapeutics Inc (INKT) | $47.95M | N/A | 236.3x | 0.0% | N/A | 0.0% | 0.00% |
| NRX Pharmaceuticals Inc (NRXP) | $95.58M | N/A | 23.8x | 0.0% | N/A | 0.0% | 0.00% |
| OnKure Therapeutics, Inc. (OKUR) | $108.33M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cardiff Oncology Inc (CRDF) | $56.49M | N/A | 115.5x | 0.0% | N/A | -14.1% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Champions Oncology Inc (CSBR) | $65.49M | N/A | 1.0x | -1.9% | N/A | 8.8% | 0.00% |
| Actinium Pharmaceuticals Inc (ATNM) | $51.56M | 4.1x | 1.3x | 32.2% | N/A | -100.0% | 0.00% |
| Neumora Therapeutics, Inc. (NMRA) | $80.59M | N/A | N/A | 0.0% | -260.5% | 0.0% | 0.00% |
| Kazia Therapeutics Ltd ADR (KZIA) | $75.65M | N/A | N/A | 0.0% | N/A | 312.4% | 0.00% |
| Cingulate Inc (CING) | $62.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $78.12M | 4.1x | 23.8x | 0.0% | -260.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Nkarta, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Mink Therapeutics Inc (INKT) | MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic... | INKT competitors |
| NRX Pharmaceuticals Inc (NRXP) | NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company... | NRXP competitors |
| OnKure Therapeutics, Inc. (OKUR) | OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. | OKUR competitors |
| Cardiff Oncology Inc (CRDF) | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. | CRDF competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Champions Oncology Inc (CSBR) | Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. | CSBR competitors |
| Actinium Pharmaceuticals Inc (ATNM) | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation... | ATNM competitors |
| Neumora Therapeutics, Inc. (NMRA) | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases... | NMRA competitors |
| Kazia Therapeutics Ltd ADR (KZIA) | Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia. | |
| Cingulate Inc (CING) | Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous... | CING competitors |
Frequently Asked Questions About NKTX
Who are Nkarta's main competitors?
The companies most similar to Nkarta include Mink Therapeutics (INKT), NRX Pharmaceuticals (NRXP), OnKure Therapeutics (OKUR), Cardiff Oncology (CRDF) and Protara Therapeutics (TARA), listed from the closest match.
Who is Nkarta's biggest competitor?
Protara Therapeutics (TARA) is the largest of the similar companies at $155.77M; Mink Therapeutics (INKT) is the closest match by business profile, size, sector and industry.
How does NKTX stock compare with its competitors?
NKTX's net margin is 0.0% against a peer median of 0.0%.
Which of Nkarta's competitors pays a higher dividend?
Nkarta pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Nkarta bigger than its competitors?
No. Nkarta is 6th by market cap among the 13 companies on this page; the largest is Protara Therapeutics (TARA) at $155.77M.
NKTX pages: Overview, Earnings, Forecast, Financials, Competitors